{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:24:42Z","timestamp":1793330682026,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The natural course of metabolic dysfunction-associated steatotic liver disease (MASLD) in the population with metabolically healthy obesity (MHO) has not been adequately explored. In the present narrative review, we summarize the evidence regarding the association between MHO and MASLD prevalence, incidence and progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Cross-sectional, population-based, cohort studies have shown an increased prevalence of hepatic steatosis and fibrosis in subjects with MHO compared with metabolically healthy non-obese individuals (MHNO). In large-scale longitudinal cohort studies among metabolically healthy subjects, increasing body mass index (BMI) has been found to be independently associated with an increased incidence of MASLD and progressive hepatic fibrosis over a mean follow-up period of 2.2\u20137.7 years. With regard to advanced MASLD, the prevalence of steatohepatitis and clinically significant liver fibrosis is lower in MHO compared with subjects with metabolically unhealthy obesity (MUO). The presence of MASLD has been proposed as a strong risk factor for metabolic health deterioration in MHO. Furthermore, subjects with MHO and MASLD display an elevated 10-year cardiovascular risk and a three-fold increased risk of incident diabetes compared with MHO without MASLD. MASLD may also predict the failure to convert from MUO to MHO after a weight loss intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-025-00637-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:07:25Z","timestamp":1747627645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression"],"prefix":"10.1007","volume":"14","author":[{"given":"Chrysi","family":"Koliaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dalamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kakounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Liatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"637_CR1","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, Beverly EA, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in Diabetes\u20142025. Diabetes Care. 2025;48:S59\u201385.","journal-title":"Diabetes Care"},{"key":"637_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"637_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"637_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"637_CR5","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702.","journal-title":"Gut"},{"key":"637_CR6","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","volume":"146","author":"P Golabi","year":"2023","unstructured":"Golabi P, Paik JM, Kumar A, Al Shabeeb R, Eberly KE, Cusi K, et al. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the united States. Metabolism. 2023;146:155642.","journal-title":"Metabolism"},{"key":"637_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999\u2013e20108.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"637_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"637_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"637_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"637_CR11","doi-asserted-by":"crossref","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014. e1.","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"637_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"637_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375\u201382.","journal-title":"Gut"},{"key":"637_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13:134\u201348.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"637_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"key":"637_CR16","doi-asserted-by":"crossref","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157:155937.","DOI":"10.1016\/j.metabol.2024.155937"},{"key":"637_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s13679-023-00494-4","volume":"12","author":"BJ Mathis","year":"2023","unstructured":"Mathis BJ, Tanaka K, Hiramatsu Y. Metabolically healthy obesity: are interventions useful?? Curr Obes Rep. 2023;12:36\u201360.","journal-title":"Curr Obes Rep"},{"key":"637_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2213-8587(18)30137-2","volume":"6","author":"N Eckel","year":"2018","unstructured":"Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90\u2008257 women (the nurses\u2019 health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6:714\u201324.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"637_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3803\/EnM.2020.301","volume":"35","author":"N Stefan","year":"2020","unstructured":"Stefan N. Metabolically healthy and unhealthy normal weight and obesity. Endocrinol Metab. 2020;35:487\u201393.","journal-title":"Endocrinol Metab"},{"key":"637_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.metabol.2018.11.009","volume":"92","author":"C Iacobini","year":"2019","unstructured":"Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51\u201360.","journal-title":"Metabolism"},{"key":"637_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41574-024-01008-5","volume":"20","author":"MB Schulze","year":"2024","unstructured":"Schulze MB, Stefan N. Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications. Nat Rev Endocrinol. 2024;20:633\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"637_CR22","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1001\/archinte.168.15.1609","volume":"168","author":"N Stefan","year":"2008","unstructured":"Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609\u201316.","journal-title":"Arch Intern Med"},{"key":"637_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19:359\u201366.","journal-title":"Ann Hepatol"},{"key":"637_CR24","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.2147\/DMSO.S431251","volume":"16","author":"Y Ding","year":"2023","unstructured":"Ding Y, Deng Q, Yang M, Niu H, Wang Z, Xia S. Clinical classification of obesity and implications for metabolic Dysfunction-Associated fatty liver disease and treatment. Diabetes Metab Syndr Obes. 2023;16:3303\u201329.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"637_CR25","doi-asserted-by":"publisher","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","volume":"41","author":"M Bl\u00fcher","year":"2020","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):bnaa004.","journal-title":"Endocr Rev"},{"key":"637_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1472-6823-14-9","volume":"14","author":"JV van Vliet-Ostaptchouk","year":"2014","unstructured":"van Vliet-Ostaptchouk JV, Nuotio M-L, Slagter SN, Doiron D, Fischer K, Foco L, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.","journal-title":"BMC Endocr Disord"},{"key":"637_CR27","doi-asserted-by":"publisher","first-page":"e8838","DOI":"10.1097\/MD.0000000000008838","volume":"96","author":"H Lin","year":"2017","unstructured":"Lin H, Zhang L, Zheng R, Zheng Y. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant Article. Medicine. 2017;96:e8838.","journal-title":"Medicine"},{"key":"637_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/obr.12198","volume":"15","author":"JP Rey-L\u00f3pez","year":"2014","unstructured":"Rey-L\u00f3pez JP, de Rezende LF, Pastor-Valero M, Tess BH. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15:781\u201390.","journal-title":"Obes Rev"},{"key":"637_CR29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2047487315623884","volume":"23","author":"N Eckel","year":"2016","unstructured":"Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23:956\u201366.","journal-title":"Eur J Prev Cardiol"},{"key":"637_CR30","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jacc.2018.02.055","volume":"71","author":"M Mongraw-Chaffin","year":"2018","unstructured":"Mongraw-Chaffin M, Foster MC, Anderson CAM, Burke GL, Haq N, Kalyani RR, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71:1857\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"637_CR31","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.jacc.2018.08.1037","volume":"72","author":"CJ Lavie","year":"2018","unstructured":"Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol. 2018;72:1506\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"637_CR32","doi-asserted-by":"publisher","first-page":"e218505","DOI":"10.1001\/jamanetworkopen.2021.8505","volume":"4","author":"A Zembic","year":"2021","unstructured":"Zembic A, Eckel N, Stefan N, Baudry J, Schulze MB. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 2021;4:e218505.","journal-title":"JAMA Netw Open"},{"key":"637_CR33","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/oby.20227","volume":"21","author":"M Peppa","year":"2013","unstructured":"Peppa M, Koliaki C, Papaefstathiou A, Garoflos E, Katsilambros N, Raptis SA, et al. Body composition determinants of metabolic phenotypes of obesity in Nonobese and obese postmenopausal women. Obesity. 2013;21:1807\u201314.","journal-title":"Obesity"},{"key":"637_CR34","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1152\/ajpendo.00586.2009","volume":"299","author":"N Kl\u00f6ting","year":"2010","unstructured":"Kl\u00f6ting N, Fasshauer M, Dietrich A, Kovacs P, Sch\u00f6n MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299:E506\u201315.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"637_CR35","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","volume":"70","author":"R Caleyachetty","year":"2017","unstructured":"Caleyachetty R, Thomas GN, Toulis KA, Mohammed N, Gokhale KM, Balachandran K, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70:1429\u201337.","journal-title":"J Am Coll Cardiol"},{"key":"637_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/jech-2015-206948","volume":"70","author":"R Zheng","year":"2016","unstructured":"Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health (1978). 2016;70:1024\u201331.","journal-title":"J Epidemiol Community Health (1978)"},{"key":"637_CR37","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41366-018-0096-z","volume":"43","author":"O Moussa","year":"2019","unstructured":"Moussa O, Arhi C, Ziprin P, Darzi A, Khan O, Purkayastha S. Fate of the metabolically healthy obese-is this term a misnomer? A study from the clinical practice research datalink. Int J Obes (Lond). 2019;43:1093\u2013101.","journal-title":"Int J Obes (Lond)"},{"key":"637_CR38","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/0003-4819-159-11-201312030-00008","volume":"159","author":"CK Kramer","year":"2013","unstructured":"Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med. 2013;159:758\u201369.","journal-title":"Ann Intern Med"},{"key":"637_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12902-024-01630-4","volume":"24","author":"F Najafi","year":"2024","unstructured":"Najafi F, Pasdar Y, Nazar MM, Darbandi M. Association between obesity phenotypes and non-alcoholic fatty liver: a large population-based study. BMC Endocr Disord. 2024;24:96.","journal-title":"BMC Endocr Disord"},{"key":"637_CR40","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s12072-022-10395-8","volume":"16","author":"S Man","year":"2022","unstructured":"Man S, Lv J, Yu C, Deng Y, Yin J, Wang B, et al. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int. 2022;16:1412\u201323.","journal-title":"Hepatol Int"},{"key":"637_CR41","doi-asserted-by":"publisher","first-page":"101754","DOI":"10.1016\/j.clinre.2021.101754","volume":"45","author":"H Tutunchi","year":"2021","unstructured":"Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, Mobasseri M, Ostadrahimi A. Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study. Clin Res Hepatol Gastroenterol. 2021;45:101754.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"637_CR42","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1111\/jgh.15544","volume":"36","author":"TP Chen","year":"2021","unstructured":"Chen TP, Lin WY, Chiang CH, Shen TH, Huang KC, Yang KC. Metabolically healthy obesity and risk of non-alcoholic fatty liver disease severity independent of visceral fat. J Gastroenterol Hepatol. 2021;36:2903\u201310.","journal-title":"J Gastroenterol Hepatol"},{"key":"637_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12902-020-00582-9","volume":"20","author":"A Vusirikala","year":"2020","unstructured":"Vusirikala A, Thomas T, Bhala N, Tahrani AA, Tahrani AA, Tahrani AA, et al. Impact of obesity and metabolic health status in the development of non-alcoholic fatty liver disease (NAFLD): A united Kingdom population-based cohort study using the health improvement network (THIN). BMC Endocr Disord. 2020;20:96.","journal-title":"BMC Endocr Disord"},{"key":"637_CR44","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/liv.14184","volume":"39","author":"Y Kim","year":"2019","unstructured":"Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39:1884\u201394.","journal-title":"Liver Int"},{"key":"637_CR45","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15015","volume":"48","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, Aller R, Gallego-Dur\u00e1n R, Banales JM, Crespo J, Garc\u00eda\u2010Monz\u00f3n C, et al. The effects of metabolic status on non\u2010alcoholic fatty liver disease\u2010related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260\u201370.","journal-title":"Aliment Pharmacol Ther"},{"key":"637_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.diabet.2017.02.007","volume":"43","author":"Y Guti\u00e9rrez-Grobe","year":"2017","unstructured":"Guti\u00e9rrez-Grobe Y, Ju\u00e1rez-Hern\u00e1ndez E, S\u00e1nchez-Jim\u00e9nez BA, Uribe-Ramos MH, Ramos-Ostos MH, Uribe M, et al. Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease. Diabetes Metab. 2017;43:332\u20137.","journal-title":"Diabetes Metab"},{"key":"637_CR47","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ajg.2016.178","volume":"111","author":"Y Chang","year":"2016","unstructured":"Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133\u201340.","journal-title":"Am J Gastroenterol"},{"key":"637_CR48","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3803\/EnM.2015.30.4.522","volume":"30","author":"MK Lee","year":"2015","unstructured":"Lee MK, Rhee EJ, Kim MC, Moon BS, Lee JI, Song YS, et al. Metabolic health is more important than obesity in the development of nonalcoholic fatty liver disease: A 4-year retrospective study. Endocrinol Metab. 2015;30:522\u201330.","journal-title":"Endocrinol Metab"},{"key":"637_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.numecd.2013.07.005","volume":"24","author":"K-C Sung","year":"2014","unstructured":"Sung K-C, Cha S-C, Sung J-W, So M-S, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutr Metab Cardiovasc Dis. 2014;24:256\u201362.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"637_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.metabol.2016.10.003","volume":"66","author":"JH Huh","year":"2017","unstructured":"Huh JH, Kim KJ, Kim SU, Han SH, Han K-H, Cha B-S, et al. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism. 2017;66:23\u201331.","journal-title":"Metabolism"},{"key":"637_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.soard.2017.11.032","volume":"14","author":"IN Haskins","year":"2018","unstructured":"Haskins IN, Chang J, Nor Hanipah Z, Singh T, Mehta N, McCullough AJ, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? Surg Obes Relat Dis. 2018;14:342\u20136.","journal-title":"Surg Obes Relat Dis"},{"key":"637_CR52","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.3390\/ijms15058591","volume":"15","author":"W Peverill","year":"2014","unstructured":"Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591\u2013638.","journal-title":"Int J Mol Sci"},{"key":"637_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12967-022-03850-5","volume":"21","author":"J Zheng","year":"2023","unstructured":"Zheng J, Li X, Zhang Y, Miao Y, Zhang Q. Hyperuricemia as an effect modifier of the association between metabolic phenotypes and nonalcoholic fatty liver disease in Chinese population. J Transl Med. 2023;21:39.","journal-title":"J Transl Med"},{"key":"637_CR54","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender S, Kozlitina J, Nordestgaard BG, Tybj\u00e6rg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49:842\u20137.","journal-title":"Nat Genet"},{"key":"637_CR55","doi-asserted-by":"publisher","first-page":"115925","DOI":"10.1016\/j.bcp.2023.115925","volume":"218","author":"M Meroni","year":"2023","unstructured":"Meroni M, Chiappori F, Paolini E, Longo M, De Caro E, Mosca E, et al. A novel gene signature to diagnose MASLD in metabolically unhealthy obese individuals. Biochem Pharmacol. 2023;218:115925.","journal-title":"Biochem Pharmacol"},{"key":"637_CR56","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.2337\/dc12-1971","volume":"36","author":"SL Appleton","year":"2013","unstructured":"Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013;36:2388\u201394.","journal-title":"Diabetes Care"},{"key":"637_CR57","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1210\/jc.2012-4253","volume":"98","author":"F Soriguer","year":"2013","unstructured":"Soriguer F, Guti\u00e9rrez-Repiso C, Rubio-Mart\u00edn E, Garc\u00eda-Fuentes E, Almaraz MC, Colomo N, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98:2318\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"637_CR58","doi-asserted-by":"publisher","first-page":"e3384","DOI":"10.1097\/MD.0000000000003384","volume":"95","author":"NH Kim","year":"2016","unstructured":"Kim NH, Seo JA, Cho H, Seo JH, Yu JH, Yoo HJ, et al. Risk of the development of diabetes and cardiovascular disease in metabolically healthy obese people: the Korean genome and epidemiology study. Medicine. 2016;95:e3384.","journal-title":"Medicine"},{"key":"637_CR59","doi-asserted-by":"publisher","first-page":"e1705","DOI":"10.1097\/MD.0000000000001705","volume":"94","author":"S-H Lee","year":"2015","unstructured":"Lee S-H, Yang HK, Ha H-S, Lee J-H, Kwon H-S, Park Y-M, et al. Changes in metabolic health status over time and risk of developing type 2 diabetes: A prospective cohort study. Medicine. 2015;94:e1705.","journal-title":"Medicine"},{"key":"637_CR60","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1530\/EJE-15-0449","volume":"173","author":"M Hamer","year":"2015","unstructured":"Hamer M, Bell JA, Sabia S, Batty GD, Kivim\u00e4ki M. Stability of metabolically healthy obesity over 8 years: the english longitudinal study of ageing. Eur J Endocrinol. 2015;173:703\u20138.","journal-title":"Eur J Endocrinol"},{"key":"637_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jacc.2014.09.077","volume":"65","author":"JA Bell","year":"2015","unstructured":"Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 2015;65:101\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"637_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ijo.2016.179","volume":"41","author":"GC Kabat","year":"2017","unstructured":"Kabat GC, Wu WY-Y, Bea JW, Chen C, Qi L, Stefanick ML, et al. Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women. Int J Obes (Lond). 2017;41:170\u20137.","journal-title":"Int J Obes (Lond)"},{"key":"637_CR63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4093\/dmj.2017.41.6.430","volume":"41","author":"E Han","year":"2017","unstructured":"Han E, Lee YH. Non-Alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal diseases. Diabetes Metab J. 2017;41:430\u20137.","journal-title":"Diabetes Metab J"},{"key":"637_CR64","doi-asserted-by":"publisher","first-page":"154893","DOI":"10.1016\/j.metabol.2021.154893","volume":"128","author":"M Kouvari","year":"2022","unstructured":"Kouvari M, Chrysohoou C, Skoumas J, Pitsavos C, Panagiotakos DB, Mantzoros CS. The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study. Metabolism. 2022;128:154893.","journal-title":"Metabolism"},{"key":"637_CR65","doi-asserted-by":"publisher","first-page":"14786","DOI":"10.1038\/s41598-022-18988-x","volume":"12","author":"L Lei","year":"2022","unstructured":"Lei L, Changfa W, Jiangang W, Zhiheng C, Ting Y, Xiaoling Z, et al. Association between non-alcoholic fatty liver disease and metabolically healthy deterioration across different body shape phenotypes at baseline and change patterns. Sci Rep. 2022;12:14786.","journal-title":"Sci Rep"},{"key":"637_CR66","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/oby.22536","volume":"27","author":"YC Hwang","year":"2019","unstructured":"Hwang YC, Ahn HY, Park CY. Association between nonalcoholic fatty liver disease and future deterioration of metabolic health: A cohort study. Obesity. 2019;27:1360\u20136.","journal-title":"Obesity"},{"key":"637_CR67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-8587(17)30292-9","volume":"6","author":"N Stefan","year":"2018","unstructured":"Stefan N, H\u00e4ring H-U, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6:249\u201358.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"637_CR68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","volume":"68","author":"A Lonardo","year":"2018","unstructured":"Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68:335\u201352.","journal-title":"J Hepatol"},{"key":"637_CR69","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"637_CR70","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","volume":"55","author":"G Musso","year":"2012","unstructured":"Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885\u2013904.","journal-title":"Diabetologia"},{"key":"637_CR71","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u2013e3785.","journal-title":"Gastroenterology"},{"key":"637_CR72","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/j.cgh.2021.04.037","volume":"20","author":"IY Cho","year":"2022","unstructured":"Cho IY, Chang Y, Sung E, Kang JH, Shin H, Wild SH, et al. Weight change and the development of nonalcoholic fatty liver disease in metabolically healthy overweight individuals. Clin Gastroenterol Hepatol. 2022;20:e583\u201399.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"637_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.orcp.2024.02.007","volume":"18","author":"S Man","year":"2024","unstructured":"Man S, Deng Y, Ma Y, Yang X, Wang X, Fu J, et al. Association between weight change, waist circumference change, and the risk of nonalcoholic fatty liver disease in individuals with metabolically healthy overweight or obesity and metabolically unhealthy overweight or obesity. Obes Res Clin Pract. 2024;18:109\u201317.","journal-title":"Obes Res Clin Pract"},{"key":"637_CR74","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cgh.2022.04.012","volume":"21","author":"H Park","year":"2023","unstructured":"Park H, Yoon EL, Kim M, Cho S, Nah EH, Jun DW. Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): considerable proportions of MAFLD are metabolic healthy. Clin Gastroenterol Hepatol. 2023;21:1041\u2013e10493.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"637_CR75","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cgh.2022.05.010","volume":"21","author":"Y Fouad","year":"2023","unstructured":"Fouad Y, Zheng M-H. Metabolically healthy obese MAFLD: are they truly healthy? Clin Gastroenterol Hepatol. 2023;21:857\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"637_CR76","doi-asserted-by":"publisher","first-page":"e002362","DOI":"10.1136\/bmjdrc-2021-002362","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang J, Xu Q, Lai F, Chen N, Lin M, Liu Y, et al. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. BMJ Open Diabetes Res Care. 2021;9(1):e002362.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"637_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.orcp.2017.12.003","volume":"12","author":"Y Hashimoto","year":"2018","unstructured":"Hashimoto Y, Hamaguchi M, Tanaka M, Obora A, Kojima T, Fukui M. Metabolically healthy obesity without fatty liver and risk of incident type 2 diabetes: A meta-analysis of prospective cohort studies. Obes Res Clin Pract. 2018;12:4\u201315.","journal-title":"Obes Res Clin Pract"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-025-00637-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-025-00637-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:03:48Z","timestamp":1747631028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-025-00637-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s13679-025-00637-9","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"5 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Metabolically healthy obesity and MASLD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Short Running Title"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"46"}}